| Patient | Ella Fitzgerald |
|---|---|
| Date of birth | 1917-04-25 |
| Identifiers | MRN HR-ML029-SYN-TD; SSN (made up) 000-29-3640 |
| Document date | 1987-08-10 |
| Author | Odessa Whitlow, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review: A1c, lipids, walking program, eye treatment, and foot care. [S]
Ms. Fitzgerald returns three months after her first visit, after a two-week run of concerts. She completed ten weeks of the supervised exercise program and walked to the home plan on tour; she can now walk about three blocks before calf pain, and the pain eases faster. She has had three right-eye injections, and her right eye is clearer. The podiatrist pared her calluses and she now performs in low-heeled custom stage shoes. Her glucose monitor shows time in range 66% and time below 70 mg/dL 0.8%, with no reading below 54 mg/dL; she ate before every late show. She has had no bleeding on rivaroxaban and aspirin. Her hepatitis C screening test was negative. She would like to know whether anything else can help her legs and her glucose. [S]
| Element | Detail |
|---|---|
| Glucose | Time in range 66%; time below 70 mg/dL 0.8%; none below 54 |
| Walking | About three blocks, from one and a half |
| Eye treatment | Three right-eye injections; vision clearer |
| Feet | Calluses pared; low-heeled stage shoes |
| Bleeding | None |
| System | Result | Finding |
|---|---|---|
| Cardiovascular | Positive | Calf pain after about three blocks; no chest pain or rest pain |
| Eyes | Positive | Right-eye blur better |
| Hematologic | Negative | No bruising, nosebleeds, or blood in the urine or stool |
| Integumentary | Negative | No foot sores |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with breakfast and the evening meal | Oral route | 1977-03-01 | active | S |
| Glipizide 10 mg oral tablet, one tablet by mouth twice daily before meals | One tablet by mouth twice daily before breakfast and the evening meal | Oral route | 1982-09-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 30 units under the skin at bedtime | 30 units at bedtime | Subcutaneous route | 1984-04-01 to 1987-05-11 | completed | S |
| Insulin glargine 100 units/mL pen, 24 units under the skin each morning | 24 units each morning, at the same clock time on tour, with written time-zone adjustments | Subcutaneous route | 1987-05-11 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 to 1987-05-11 | completed | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1987-05-11 | active | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1986-06-02 | active | S |
| Empagliflozin 10 mg oral tablet, one tablet by mouth each morning | One tablet by mouth each morning; hold on days she cannot eat or drink normally and before surgery | Oral route | 1987-05-11 | active | S |
| Glucagon 3 mg nasal powder, one spray into one nostril for a severe low glucose | One spray into one nostril if she cannot safely swallow during a low glucose; may repeat once after 15 minutes with a new device; call 911 | Nasal route | 1987-05-11 | active | S |
| Rivaroxaban 2.5 mg oral tablet, one tablet by mouth twice daily with aspirin 81 mg | One tablet by mouth twice daily, with aspirin 81 mg once daily | Oral route | 1987-05-26 | active | S |
| Semaglutide 0.25 mg under the skin once weekly for four weeks | 0.25 mg once weekly on the same day each week for four weeks | Subcutaneous route | 1987-08-10 to 1987-09-07 | completed | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1987-08-10 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1987-08-10 | Body height | 165 | cm | S |
| 1987-08-10 | Body weight | 82.1 | kg | S |
| 1987-08-10 | Body mass index (BMI) [Ratio] | 30.2 | kg/m2 | S |
| 1987-08-10 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1987-08-10 | Diastolic blood pressure | 68 | mm[Hg] | S |
| 1987-08-10 | Heart rate | 62 | /min | S |
| 1987-08-10 | Respiratory rate | 16 | /min | S |
| 1987-08-10 | Body temperature | 36.6 | Cel | S |
| 1987-08-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1987-08-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.6 | % | Below 5.7% is normal; her individualized goal is below 7.5% | High | S |
| 1987-08-10 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1987-08-10 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1987-08-10 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 1987-08-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1982)/1.73 sq M | 64 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1987-08-10 | Cholesterol [Mass/volume] in Serum or Plasma | 128 | mg/dL | <=199 mg/dL | Normal | S |
| 1987-08-10 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 64 | mg/dL | Her goal with coronary and peripheral artery disease is below 55 mg/dL | Normal | S |
| 1987-08-10 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=50 mg/dL | Low | S |
| 1987-08-10 | Triglyceride [Mass/volume] in Serum or Plasma | 112 | mg/dL | <=149 mg/dL | Normal | S |
| 1987-08-10 | Visual acuity best corrected Right eye by ETDRS eye chart | 71 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Low | S |
| 1987-08-10 | Visual acuity best corrected Left eye by ETDRS eye chart | 81 | {letters} | 85 letters is about 20/20; 80 about 20/25; 65 about 20/50 | Normal | S |
Vital signs recorded on 1987-08-10; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 82.1 kg, BMI 30.2; blood pressure 122/68, pulse 62 |
| Feet | Skin intact; small calluses; hammer toes; no ulcer; monofilament felt at all sites; right foot pulses absent, left faint; shoes fit well |
| Eyes | Best-corrected acuity 71 letters right and 81 letters left |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with peripheral artery disease: cramping in both calves after about one and a half blocks of walking, worse on the right, easing within minutes of rest; no rest pain, wounds, or color change. Resting ankle-brachial index 0.62 right and 0.74 left, toe-brachial index 0.46 and 0.55; dorsalis pedis and posterior tibial pulses absent on the right and faint on the left. A1c 8.6% on metformin, glipizide and glargine, with low glucose readings (to 52 mg/dL) after late performances. Foot: protective sensation intact to the 10-g monofilament at all sites and to vibration; callus under the second metatarsal heads; hammer toes of the second and third toes; no ulcer (IWGDF risk category 2). Synthetic modern episode linked to her documented diabetes and its circulatory complications | active | confirmed | E11.51 | S — Synthetic modern diagnosis; the type of diabetes was not made public and is synthetic. |
| Moderate nonproliferative diabetic retinopathy with center-involving diabetic macular edema in the right eye (best-corrected acuity 64 letters, about 20/50) and moderate nonproliferative retinopathy without macular edema in the left eye (81 letters); lens implants in both eyes from earlier cataract surgery. Synthetic modern episode linked to her documented diabetic eye problems | active | confirmed | E11.3311 | S — Synthetic modern eye diagnosis on retinal imaging and optical coherence tomography in the clinic; the left eye is described in the display. |
| Coronary artery disease after five-vessel coronary bypass surgery last year, with an intensive care stay; no angina now; on aspirin, a statin, and metoprolol. Synthetic modern episode linked to her documented heart surgery | active | confirmed | I25.10 | S — Synthetic modern coding of her documented heart surgery; bypass grafts are described in the display. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every three months when not at goal or after a change; every six months at goal | Completed today | 7.6%, from 8.6% |
| Medication safety | Continuous glucose monitor review: time in range and time below range | Every visit | Completed today | Time in range 66%; time below 70 mg/dL 0.8%; none below 54 mg/dL |
| Medication safety | Hypoglycemia events, show-day plan, and glucagon | Every visit | Completed today | No level 2 or 3 lows; ate before every late show; glucagon unused |
| Medication safety | Empagliflozin safety: genital infection, volume, and sick-day rules | At the start and every visit | Completed today | No genital infection; no dizziness on stage |
| Laboratory | Creatinine, eGFR, and potassium | Within three months of starting an SGLT2 inhibitor, then every six to twelve months; potassium on SGLT2 inhibitor and rivaroxaban review | Completed today | Creatinine 0.96 mg/dL, eGFR 64, potassium 4.6, sodium 140 mmol/L |
| Laboratory | Urine albumin-creatinine ratio | Yearly | Up to date | 18 mg/g at intake |
| Laboratory | Lipid panel | 4 to 12 weeks after a statin or other lipid-lowering change, then yearly | Deferred | Due 4 to 12 weeks after atorvastatin was raised; drawn today at 13 weeks, one week late, because she was on tour. LDL 64 mg/dL, above goal; no harm from the one-week delay. Corrective action: lipid tests after any change are booked before she leaves on tour |
| Examination | Foot inspection, protective sensation, and pulses | Every visit with peripheral artery disease and foot deformity (IWGDF risk 2); podiatry every three to six months | Completed today | No ulcer; protective sensation intact; podiatry seen in June, next visit in September |
| Imaging | Ankle-brachial and toe-brachial indices | At diagnosis; repeat with arterial duplex six months after the consultation or with any change in symptoms | Up to date | Repeat with duplex at the six-month vascular review |
| Examination | Walking distance and claudication symptoms | Every visit | Completed today | About three blocks before calf pain, from one and a half |
| Self-management | Supervised exercise therapy | Three times a week for twelve weeks | Completed today | Ten of twelve weeks done; home plan followed on tour |
| Imaging | Retinal examination and visual acuity | With each retina-clinic treatment while macular edema is treated; at least yearly in both eyes | Completed today | Acuity 71 letters right and 81 left; three injections; retina clinic told about semaglutide |
| Examination | Blood pressure | Every visit | Completed today | 122/68 mmHg |
| Examination | Weight and BMI | Every visit | Completed today | 82.1 kg, down 1.9 kg |
| Medication safety | Bleeding on rivaroxaban and aspirin | At the start and every visit | Completed today | No bleeding |
| Medication safety | Semaglutide tolerance: nausea, appetite, and dose step | At the start and each dose step | Completed today | Starting today; nausea and dose steps explained |
| Self-management | Access and equity: tour-date scheduling, video visits, large print, drug costs | Every visit | Completed today | Semaglutide cost checked with her Part D plan; next visit set before the autumn tour |
Goal progress:
Guideline basis: Standards of Care in Diabetes—2026 (2026); Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update) (2023); 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease (2024); 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease (2023); CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and ischemic heart disease monographs (2026); Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial (2025)
Follow-up: Semaglutide dose step in four weeks, by video visit if she is touring. Podiatry in September. Review in eleven weeks with A1c, lipids, and kidney tests; zoster vaccine dose 1 at that visit. Next scheduled visit 1987-10-26: five-and-a-half-month review: A1c, lipids, walking distance, revascularization decision, foot and eye follow-up. [S]